RecruitingPhase 2NCT04644211

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Studying Essential thrombocythemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Massachusetts General Hospital
Principal Investigator
Gabriela Hobbs, MD
Massachusetts General Hospital
Intervention
Ruxolitinib(drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
2022 – 2034

Study locations (4)

Collaborators

Incyte Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04644211 on ClinicalTrials.gov

Other trials for Essential thrombocythemia

Additional recruiting or active studies for the same condition.

See all trials for Essential thrombocythemia →

← Back to all trials